Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | GNPAT | O15228 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3156486 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10CFTRGNPAT | |
| SCHEMBL31520049 | 1.00 | ALDH1A1 (0.46) | ALDH1A1KDM4EHSD17B10CFTRGNPAT | |
| SCHEMBL27372384 | 0.88 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL18796376 | 0.85 | GAA (0.46) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL19273911 | 0.85 | GAA (0.46) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL5388881 | 0.83 | MAPT (0.43) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL288333 | 0.83 | MAPT (0.43) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL4351788 | 0.82 | ALDH1A1 (0.50) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL17483636 | 0.82 | ALDH1A1 (0.48) | ALDH1A1KDM4EHSD17B10CFTRMAPT | |
| SCHEMBL4996617 | 0.82 | MAPT (0.42) | ALDH1A1KDM4EHSD17B10CFTRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| CN-118435054-A | Compositions and methods for diagnosing and treating chronic kidney disease | 雀巢产品有限公司 | 2024-08-02 | — | — | CN | claimed |
| US-20230204604-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-06-29 | — | — | US | claimed |
| US-12635713-B2 | Pet food compositions | HILL'S PET NUTRITION, INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | UNIV CALIFORNIA (US) | 2026-03-19 | — | — | US | disclosed |
| US-12553902-B2 | Methods, kits and compositions for diagnosing and treating renal disease | HILL'S PET NUTRITION, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | UNIV CALIFORNIA (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250295713-A1 | COMPOSITIONS AND METHODS FOR IMPROVING SKIN HEALTH AND FOR THE TREATMENT AND PREVENTION OF DISEASES, DISORDERS AND CONDITIONS ASSOCIATED WITH PATHOGENIC MICROBES | DERMBIONT, INC. | 2025-09-25 | — | — | US | disclosed |
| EP-4457513-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE | Société des Produits Nestlé S.A. (CH) | 2024-11-06 | — | — | EP | disclosed |
| US-12064459-B2 | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | DERMBIONT, INC. (US) | 2024-08-20 | — | — | US | disclosed |
| US-20190201360-A1 | TREATMENT OF DISEASE WITH N-ACETYL KYNURENINE | AMPIO PHARMACEUTICALS, INC. | 2019-07-04 | — | — | US | disclosed |
| US-20180140553-A1 | NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF | APET Holding B.V. (NL) | 2018-05-24 | — | — | US | disclosed |
| WO-2018044724-A1 | TREATMENT OF DISEASE WITH N-ACETYL KYNURENINE | AMPIO PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20170370954-A1 | Biomarkers for Fatty Liver Disease and Methods Using the Same | METABOLON, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170241043-A1 | PREDICTING METABOLIC SIDE EFFECTS OF TRANSPORTED DRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-08-24 | — | — | US | disclosed |
| WO-2017015660-A1 | PREVENTION AND TREATMENT OF AGING AND NEURODEGENERATIVE DISEASES | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-01-26 | — | — | WO | disclosed |
| US-20140234409-A1 | NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF | APET Holding B.V. | 2014-08-21 | — | — | US | disclosed |
| EP-2731609-A1 | NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF | APeT Holding B.V. (NL) | 2014-05-21 | — | — | EP | disclosed |
| WO-2013009186-A1 | NICOTINAMIDE COMPOSITIONS AND THE THERAPEUTIC USE THEREOF | APET Holding B.V. (NL) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375505-A1 | COMPOSITIONS AND METHODS FOR MODIFYING BILE ACIDS TO REGULATE LIPID AND STEROID METABOLISM | CYP27A1, LIPC, CYP46A1 | ALDH1A1 1661/4885KDM4E 3711/4885HSD17B10 68/4885 |
| US-20260076944-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BRAIN HEALTH | IDO1, INMT, IDO2 | ALDH1A1 938/4885KDM4E 553/4885HSD17B10 565/4885 |
| US-12553902-B2 | Methods, kits and compositions for diagnosing and treating renal disease | GLS, KYNU, AADAT | ALDH1A1 3728/4885KDM4E 2454/4885HSD17B10 2027/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | ALDH1A1 822/4885KDM4E 124/4885HSD17B10 4795/4885 |
| US-12635713-B2 | Pet food compositions | FIP1L1, FAP, BECN1 | ALDH1A1 2482/4885KDM4E 2915/4885HSD17B10 3440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.